Clinical effect of combined chemotherapy with UFT, MMC and OK-432 in recurring or advanced cancer of the digestive organs

• Published in: Gan to kagaku ryoho Vol. 16; no. 2; p. 225
• Main Authors: Aoki, Y, Tabuse, Y, Tanimura, H, Katsumi, M, Asae, M, Ichimiya, G, Imai, T, Ooshima, K, Kakihara, M, Kashitani, M
• Format: Journal Article
• Language: Japanese
• Published: Japan 01-02-1989
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Digestive System Neoplasms - drug therapy; Digestive System Neoplasms - pathology; Drug Evaluation; Female; Humans; Male; Middle Aged; Mitomycin; Mitomycins - administration & dosage; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - pathology; Picibanil - administration & dosage; Remission Induction; Tegafur - administration & dosage; Uracil - administration & dosage
• ISSN: 0385-0684

The usefulness of UFTMO therapy (combined chemotherapy with UFT, MMC and OK-432) performed in 40 cases of recurring or advanced cancer of the digestive organs was investigated. According the response criteria by Koyama et al., of 40 eligible cases, the treatment was judged effective in 13, 2 CR and 11 PR cases with a response rate of 32.5%, while of the 35 complete cases, 2 CR and 9 PR cases made for 11 effective cases and a response rate of 31.4%. Side effects were observed in 58.3% of the 36 evaluated cases; of the subjective and objective side effects, however, none were serious enough to require cessation of administration, while stopping administration in the cases of abnormal laboratory findings resulted in rapid recovery. UFTMO therapy, therefore, is considered to be one of the beneficial treatments for recurring or advanced cancer of the digestive organs.